Literature DB >> 27894076

Co-expression of Piwil2/Piwil4 in nucleus indicates poor prognosis of hepatocellular carcinoma.

Guangping Zeng1, Deying Zhang1, Xing Liu1, Qing Kang1, Yiyao Fu1, Bo Tang1, Wenhao Guo1, Yuanyuan Zhang2, Guanghui Wei1, Dawei He1.   

Abstract

PURPOSE: This study aimed to explore the localization and expression of P-element-induced wimpy testis-like 2 (piwil2)/Piwil4 in hepatocellular carcinoma (HCC) tissues, and analyze the correlation between co-expression pattern and prognosis of HCC.
RESULTS: Piwil2 showed 100% positive expression in the cell nucleus, with the intensity higher than in the cytoplasm. Piwil4 showed a lower intensity of expression in the cell nucleus than in the cytoplasm. The molecular chaperone Piwil2/Piwil4 had four co-expression patterns: nuclear co-expression, nuclear and cytoplasmic co-expression, cytoplasmic co-expression, and non-coexpression. The survival rate and the overall survival sequentially increased. The prognostic phenotype of the nuclear co-expression of Piwil2/Piwil4 was worse than that of non-coexpression, and the intracellular localization and expression of Piwil2 and Piwil4 were not significantly different.
METHODS: HCC pathological tissue samples with follow-up information (90 cases) and 2 normal control liver tissues were collected and made into a 92-site microarray. The expression of Piwil2 and Piwil4 was detected using the immunofluorescence double staining method. The differences in the expression and location of Piwil2 and Piwil4 in tumor cells were explored, and the influence of such differences on the long-term survival rate of HCC was studied using Kaplan-Meier survival curve and log-rank test. The clinical staging was analyzed according to the HCC international TNM staging criteria.
CONCLUSIONS: The nuclear co-expression of Piwil2/Piwil4 indicated that patients with HCC had a worse prognostic phenotype. The molecular chaperone Piwil2/Piwil4 seems promising as a molecular marker for prognosis judgment; a single marker (Piwil2/Piwil4) cannot be used for prognosis judgment.

Entities:  

Keywords:  Piwil2; Piwil4; hepatocellular carcinoma; molecular chaperone; prognosis

Mesh:

Substances:

Year:  2017        PMID: 27894076      PMCID: PMC5354858          DOI: 10.18632/oncotarget.13491

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Primary liver cancer is one of the most common malignant tumors of the digestive system, of which 80%-90% is hepatocellular carcinoma (HCC). The morbidity and fatality rates rank fifth and third, respectively, among the malignant tumors in the world [1, 2]. Radical excision is the main surgical treatment for liver cancer, but the high metastasis and relapse rates after operation severely affect the long-term survival of patients with HCC. P-element-induced wimpy testis (PIWI) protein plays an important role in stem cell self-renewal, spermatogenesis, RNA interference (RNAi), transposon silencing, transcriptional control, genetic recombination, genetic programming, and so on [3-5]. Piwil2 is the key regulation gene for self-renewal of germ stem cells, and it regulates the self-renewal of germ stem cells and orderly development of sperms cooperatively with molecular chaperone Piwil4 [6-8]. It has been reported that the expression of Piwil2 and Piwil4 in malignant tumors may be related to the occurrence, development, and prognosis of tumors [9-11]. Piwil2 protein activates the STAT3/Bcl-XL pathway to inhibit apoptosis, which is widely expressed in various tumors [12]. It may greatly promote the occurrence and metastasis of tumors [10, 13–15]. The expression level of Piwil4 protein is increased in soft tissue sarcoma and colon cancer, which is importantly related to poor prognosis and increased risk of metastasis [11, 16]. However, the influence of a single marker (Piwil2 or Piwil4) on the biological behavior and long-term survival, which is used to judge the development or prognosis of tumors, is very difficult. Furthermore, the reports on the correlation between the co-expression of Piwil2/Piwil4 and the occurrence, development, and prognosis of tumors are limited. As molecular chaperones, Piwil2/Piwil4 are co-expressed and localized in the tumor tissue. Whether they can be used as the indicator for tumor development or prognosis still needs further exploration. This study used a tissue chip (high efficiency and high throughput) [17] and immunofluorescent double staining to explore the localization and expression of Piwil2/Piwil4 in HCC tissues and analyze the correlation between co-expression pattern and prognosis.

RESULTS

Expression of Piwil2 and Piwil4 in normal liver tissue

No expression of Piwil2 in the nuclear or cytoplasmic part of normal liver tissue was detected. The observation of the localization and expression of Piwil4 revealed two expression patterns: cytoplasmic expression (Piwil4 n-/c+), and non-expression (Piwil4 n-/c-), as shown in Figure 1.
Figure 1

Expression of Piwil2 and Piwil4 in the normal liver tissue

No expression of Piwil2 in the nuclear or cytoplasmic part of the normal liver tissue was detected. The observation of the localization and expression of Piwil4 revealed two expression patterns: cytoplasmic expression (Piwil4 n-/c+), and non-expression (Piwil4 n-/c-). Bar = 50 μm.

Expression of Piwil2 and Piwil4 in the normal liver tissue

No expression of Piwil2 in the nuclear or cytoplasmic part of the normal liver tissue was detected. The observation of the localization and expression of Piwil4 revealed two expression patterns: cytoplasmic expression (Piwil4 n-/c+), and non-expression (Piwil4 n-/c-). Bar = 50 μm.

Correlation between the localization and expression of Piwil2 and the prognosis of HCC

In HCC tissue chips, 4 carcinoma tissue sites were missing or could not be read; 86 sites were left in carcinoma tissues. Of 90 patients, 57 died of HCC, and the median follow-up time was 14 months (1-69 months). Among the surviving 33 patients, the median follow-up time was 57 months (46-80 months). The positive expression rate of Piwil2 in the nuclear part of carcinoma tissue was 100% (86/86), significantly higher than that in the cytoplasm [47.67% (41/86)] (Fisher exact test, P = 0.000). The fluorescence intensity in the nucleus was higher than that in the cytoplasm. The observation of the localization and expression of Piwil2 revealed two expression patterns: nuclear expression (Piwil2 n+/c-, n = 45), and nuclear and cytoplasmic expression (Piwil2 n+/c+, n = 41), as shown in Figure 2. The survival rate and the overall survival of patients with Piwil2 nuclear and cytoplasmic expression were longer than the survival rate and the overall survival of patients with nuclear expression, but the survival time analysis showed no statistically significant difference (P = 0.518) (Figure 3 and Table 1 ).
Figure 2

Immunofluorescence staining results of the localization and expression of a single marker Piwil2 in HCC tissues

The observation of the localization and expression of Piwil2 revealed two expression patterns: nuclear expression (Piwil2 n+/c-) and nuclear and cytoplasmic expression (Piwil2 n+/c+). Bar = 50 μm.

Figure 3

Correlation between the localization and expression of a single marker Piwil2 and the prognosis of HCC

The survival rate and the overall survival of patients with the nuclear and cytoplasmic expression of Piwil2 were longer than the survival rate and the overall survival of patients with nuclear expression, but the survival time analysis showed no statistically significant difference (P = 0.518).

Table 1

Correlation between the localization and expression of Piwil2 and Piwil 4 and the prognosis of HCC

VariableSurvival rateStandard deviationP value
Piwil2 localization and expression
 Piwil2 n+/c−28.9% (13/45)4.3700.518
 Piwil2n+/c+41.5% (17/41)5.155
Piwil4 localization and expression
 Piwil4n+/c− (n = 20)25.0% (5/20)4.4110.663
 Piwil4n+/c+ (n = 51)33.3% (17/51)4.525
 Piwil4n+/c− (n = 20)25.0% (5/20)4.4110.242
 Piwil4n-/c+ (n = 3)66.7% (2/3)16.602
 Piwil4n+/c− (n = 20)25.0% (5/20)4.4110.053
 Piwil4n-/c− (n = 12)50.0% (6/12)6.072
 Piwil4n+/c+ (n = 51)33.3% (17/51)4.5250.285
 Piwil4n-/c+ (n = 3)66.7% (2/3)16.602
 Piwil4n+/c+ (n = 51)33.3% (17/51)4.5250.210
 Piwil4n-/c− (n = 12)50.0% (6/12)6.072
 Piwil4n-/c+ (n = 3)66.7% (2/3)16.6020.592
 Piwil4n-/c− (n = 12)50.0% (6/12)6.072

Immunofluorescence staining results of the localization and expression of a single marker Piwil2 in HCC tissues

The observation of the localization and expression of Piwil2 revealed two expression patterns: nuclear expression (Piwil2 n+/c-) and nuclear and cytoplasmic expression (Piwil2 n+/c+). Bar = 50 μm.

Correlation between the localization and expression of a single marker Piwil2 and the prognosis of HCC

The survival rate and the overall survival of patients with the nuclear and cytoplasmic expression of Piwil2 were longer than the survival rate and the overall survival of patients with nuclear expression, but the survival time analysis showed no statistically significant difference (P = 0.518).

Correlation between the localization and expression of Piwil4 and the prognosis of HCC

The positive expression rate of Piwil4 in the cell nucleus of carcinoma tissue was 84.52% (71/84), significantly higher than that in the cytoplasm [63.1% (53/84); chi-square test, P = 0.002], but the fluorescence intensity in the nucleus was weaker than that in the cytoplasm. The observation of the localization and expression of Piwil4 revealed four expression patterns: nuclear expression (Piwil4 n+/c-, n = 20), nuclear and cytoplasmic expression (Piwil4 n+/c+, n = 51), cytoplasmic expression (Piwil4 n-/c+, n = 3), and non-coexpression (Piwil4 n-/c-, n = 12) (Figure 4). The survival rate and the overall survival for the four patterns sequentially decreased. However, the overall survival (P = 0.289) (Figure 5) and survival curve (Table 2) were not statistically significantly different.
Figure 4

Immunofluorescence staining results of the localization and expression of a single marker Piwil4 in HCC tissues

The observation of the localization and expression of Piwil4 revealed four expression patterns: nuclear expression (Piwil4 n+/c-), nuclear and cytoplasmic expression (Piwil4 n+/c+), cytoplasmic expression (Piwil4 n-/c+), and non-coexpression (Piwil4 n-/c-). Bar = 50 μm.

Figure 5

Correlation between the localization and expression of a single marker Piwil4 and the prognosis of HCC

The survival rate and the overall survival for the four patterns (nuclear expression, nuclear and cytoplasmic expression, cytoplasmic expression, and non-coexpression) sequentially decreased. However, the overall survival (P = 0.289) and the survival curve were not statistically significantly different.

Table 2

Correlation between the localization and co-expression of molecular chaperone (Piwil2/Piwil4) and the prognosis of HCC

VariableSurvival rateStandard deviationP value
Piwil2/Piwil4 localization and expression
Nuclear co-expression28.9% (13/45)4.7560.343
Nuclear and cytoplasmic co-expression41.5% (17/41)5.453
Nuclear co-expression25.0% (5/20)4.7560.436
Cytoplasmic co-expression33.3% (17/51)21.567
Nuclear co-expression25.0% (5/20)4.7560.034
Non-coexpression66.7% (2/3)
Nuclear and cytoplasmic co-expression25.0% (5/20)0.658
Cytoplasmic co-expression50.0% (6/12)
Nuclear and cytoplasmic co-expression33.3% (17/51)0.225
Non-coexpression66.7% (2/3)
Cytoplasmic co-expression33.3% (17/51)0.904
Non-coexpression50.0% (6/12)

Immunofluorescence staining results of the localization and expression of a single marker Piwil4 in HCC tissues

The observation of the localization and expression of Piwil4 revealed four expression patterns: nuclear expression (Piwil4 n+/c-), nuclear and cytoplasmic expression (Piwil4 n+/c+), cytoplasmic expression (Piwil4 n-/c+), and non-coexpression (Piwil4 n-/c-). Bar = 50 μm.

Correlation between the localization and expression of a single marker Piwil4 and the prognosis of HCC

The survival rate and the overall survival for the four patterns (nuclear expression, nuclear and cytoplasmic expression, cytoplasmic expression, and non-coexpression) sequentially decreased. However, the overall survival (P = 0.289) and the survival curve were not statistically significantly different.

Correlation between the localization and co-expression of molecular chaperone (Piwil2/Piwil4) and clinical pathological indicators of prognosis of HCC

Four co-expression patterns (seven co-expression ways) were observed: (1) nuclear co-expression, Piwil2n+/c− Piwil4n+/c−, Piwil2n+/c−Piwil4n+/c+ (n= 35); (2) nuclear and cytoplasmic co-expression, Piwil2n+/c+Piwil4n+/c+ (n = 36); (3) cytoplasmic co-expression, Piwil2n+/c+Piwil4n-/c+ (n = 2); and (4) non-coexpression, Piwil2n+/c−Piwil4n-/c+, Piwil2n+/c+Piwil4n-/c−, Piwil2n+/c−Piwil4n-/c− (n = 13) (Figure 6). The survival rates and the overall survival of the four groups sequentially decreased, which was consistent with the prognostic phenotype of patients with the localization and expression of a single marker (Piwil2 and Piwil4). They all showed a worse prognosis of positive nuclear expression. The survival rates of patients with the four co-expression patterns were not statistically significantly different (P = 0.211). The pairwise comparison of survival curves indicated that the survival rate and the overall survival of patients with no co-expression of Piwil2/Piwil4 were higher than those of patients with positive nuclear co-expression (53.8% vs. 22.9%). Furthermore, no statistical difference was found in the pairwise comparison of the survival curves of patients with other co-expression patterns (Table 2, Figure 7).
Figure 6

Immunofluorescence staining results of the localization and co-expression of molecular chaperone Piwil2/Piwil4 in HCC tissues

Four co-expression patterns (seven co-expression ways) were observed: (1) nuclear co-expression, Piwil2n+/c−Piwil4n+/c−, Piwil2n+/c−Piwil4n+/c+; (2) nuclear and cytoplasmic co-expression, Piwil2n+/c+Piwil4n+/c+; (3) cytoplasmic co-expression, Piwil2n+/c+ Piwil4n-/c+; (4) non-coexpression, Piwil2n+/c−Piwil4n-/c+, Piwil2n+/c+Piwil4n-/c−, Piwil2n+/c−Piwil4n-/c−. bar = 50 μm.

Figure 7

Correlation between the localization and co-expression of molecular chaperone Piwil2/Piwil4 and the prognosis of HCC

The survival rates and the overall survival of the four groups (nuclear co-expression, nuclear and cytoplasmic co-expression, cytoplasmic co-expression, non-coexpression) sequentially decreased. The survival rates of patients with the four co-expression patterns were not statistically significantly different (P = 0.211).

Immunofluorescence staining results of the localization and co-expression of molecular chaperone Piwil2/Piwil4 in HCC tissues

Four co-expression patterns (seven co-expression ways) were observed: (1) nuclear co-expression, Piwil2n+/c−Piwil4n+/c−, Piwil2n+/c−Piwil4n+/c+; (2) nuclear and cytoplasmic co-expression, Piwil2n+/c+Piwil4n+/c+; (3) cytoplasmic co-expression, Piwil2n+/c+ Piwil4n-/c+; (4) non-coexpression, Piwil2n+/c−Piwil4n-/c+, Piwil2n+/c+Piwil4n-/c−, Piwil2n+/c−Piwil4n-/c−. bar = 50 μm.

Correlation between the localization and co-expression of molecular chaperone Piwil2/Piwil4 and the prognosis of HCC

The survival rates and the overall survival of the four groups (nuclear co-expression, nuclear and cytoplasmic co-expression, cytoplasmic co-expression, non-coexpression) sequentially decreased. The survival rates of patients with the four co-expression patterns were not statistically significantly different (P = 0.211). In the clinical pathological indicators, tumor volume (P = 0.029) and cTNM staging (P = 0.000) were related to the prognosis of HCC. The larger the volume, the higher the cTNM staging, the worse the long-term survival rate. Other indicators had no correlation with the prognosis of HCC.

DISCUSSION

Malignant tumors severely threaten human health and obstruct social development. The metastasis, relapse, and chemoradiotherapy resistance also severely influence the patient long-term survival rate, which needs to be solved. HCC is one of the most common malignant tumors in the digestive system. The high morbidity, high fatality, and high postoperative metastasis relapse rates severely affect the long-term survival of patients with HCC [18]. Therefore, it is crucial to explore a new effective biological indicator to perform prognosis judgment or develop a new adjuvant therapy as a target. In the evolutionary process, the phenomenon that involves the specific degradation of highly conserved and isogenous mRNA induced by exogenous or endogenous double-strand RNA (dsRNA) is called RNAi, which is an important mechanism for post-transcriptional gene silencing (PTGS) [19-21]. The PIWI family (core components of RNAi) is one of the two subfamilies (AGO and PIWI) of the Argonaute protein family, including PAZ and PIWI structural domains [3, 22]. The PIWI subfamily was first found in germ stem cells from Drosophila by Lin et al. in 1997 [23]. It was found to play a very important role in the self-renewal of stem cells, spermatogenesis, RNAi, transposon silencing, transcription regulation, genetic recombination, genetic programming, and so on [3-5]. The human PIWI gene family has four members: Piwil-like 1 (Piwil1/Hiwi), Piwil-like 2 (Piwil2/Hili), Piwil-like 3 (Piwil3), and Piwil-like 4 (Piwil4/Hiwi2) [24]. Piwil2 and Piwil4 are molecular chaperones, which cooperatively regulate the self-renewal of germ stem cells and spermatogenesis [6–8, 25]. High expression of Piwil2 protein has been reported to promote tumorigenesis, and the increased expression level of Piwil4 is also related to poor prognosis and increased risk of metastasis [10, 11, 13–16]. The study indicated that the self-renewal and proliferation regulation mechanism of germ stem cells could be involved in the occurrence of cancer stem cells (CSC) [26]. Piwil2 might be the molecular marker of pretumor stem cells [15], playing an important promoting role in tumorigenesis. CSC-like cells obtained using human fibroblasts with a single transcription factor Piwil2 (unpublished) were called Piwil2-induced cancer stem cells (Piwil2-iCSC). The Piwil2-iCSC tumor tissue was proved to be an embryonal undifferentiated carcinoma, which supported the effect of Piwil2 on the occurrence and development of tumors. The increased expression level of Piwil4 was related to soft tissue sarcoma and colon cancer metastasis. A new study also demonstrated that the lack of PIWI/PiRNA involvement would lead to the occurrence of testiculoma [27]. However, all the aforementioned studies focused only on the influence of expression of a single indicator (Piwil2 or Piwil4) on tumor biological behavior and long-term survival. They could not be used to judge the occurrence and development of tumors. No reports are available on the influence of localization and co-expression of Piwil2/Piwil4 molecular chaperone on the occurrence and development of tumors. In the present study, tissue chips combined with the immunofluorescent double staining technology were used to explore the difference in the intracellular localization and expression of Piwil2 and Piwil4. Furthermore, the difference in the prognostic evaluation between Piwil2, Piwil4, and Piwil2/Piwil4 co-expression was also recorded, and the correlation between the expression of molecular chaperone and the prognosis of HCC was analyzed. The correlation between the localization and expression of a single marker (Piwil2 and Piwil4) and molecular chaperone and the prognosis of HCC was explored. Piwil2 and Piwil4 are not expressed in the nucleus of normal liver tissue. They are expressed only in the cytoplasm at a very low level. In the hepatocellular carcinoma tissues, Piwil2 showed two expression patterns (nuclear co-expression and nuclear and cytoplasmic expression) and Piwil4 showed four patterns (nuclear co-expression, nuclear and cytoplasmic co-expression, cytoplasmic co-expression, and non-coexpression). The survival rate and the overall survival showed a sequential decrease. The overall survival and the survival rate of patients with nuclear co-expression were lower the overall survival and the survival rate of patients with nuclear and cytoplasm co-expression, cytoplasmic co-expression, and non-coexpression, which was consistent with the result of a single marker. The survival rate and the overall survival of patients with no co-expression of Piwil2/Piwil4 were higher than those of patients with positive nuclear co-expression (53.8% vs. 22.9%) (P = 0.034). The nuclear co-expression of Piwil2/Piwil4 indicated worse prognosis of HCC. Therefore, it could be deduced that the difference in the localization of Piwil2 and Piwil4 in tumor cells could be related to the malignant degree or prognostic phenotype of HCC. The expression in the cell nucleus could promote HCC to develop into a more malignant or worse prognostic phenotype. The co-expression and localization of molecular chaperone Piwil2/Piwil4 in the tumor tissue could be used as an indicator for tumor prognosis. It was conjectured that the change in the expression and localization of Piwil2/Piwil4 protein in HCC tissues could predict the prognosis. The transformation from the negative expression to the positive expression of Piwil2/Piwil4 protein in the cytoplasm indicated that the tumors were precancerous lesions or in the initial stage of tumorigenesis. The transformation from the negative expression of Piwil2/Piwil4 protein in the cytoplasm to the positive expression in the nucleus indicated that the tumor became more malignant. When the expression of Piwil2/Piwil4 protein disappeared in the cytoplasm and remained only in the nucleus, it suggested bad prognosis of HCC. So far, the detailed molecular biological mechanism underlying the influence of Piwil2 and Piwil4 on the occurrence, development, and prognosis of HCC is still unclear, which needs further exploration. The present study was the first to perform such correlation analysis as well as explore the correlation between the cytoplasmic co-expression of Piwil2/Piwil4 and the prognosis of HCC. The molecular chaperone Piwil2/Piwil4 seems quite promising as an important molecular marker for prognosis judgment, and a single marker (Piwil2 or Piwil4) cannot be used as the indicator for the prognosis of HCC. In the enrolled 90 cases, the patients died of HCC in the follow-up, accounting for 63.33% (57 cases) of the patients in the study. In the 33 survivors, the median follow-up time was 57 months (46-80 months), of which the follow-up time of 21 patients did not reach 5 years. The molecular biological mechanism could not be explored due to the limited sample size and follow-up time. Large-sample studies will be helpful in analyzing the correlation between the co-expression of Piwil2/Piwil4 and the prognosis of HCC. They can provide the theoretical basis for the molecular marker of early-stage diagnostic and prognostic evaluation, and targeted tumor therapies.

MATERIALS AND METHODS

HCC sample source

All the 90 HCC and 2 normal control samples were obtained from the tissue bank of Shanghai Outdo Biotech Co., Ltd. (HLiv-HCC180Sur-04). All the tumor samples were diagnosed with HCC and did not receive chemotherapy or radiotherapy. Two normal control samples were obtained from two male adult patients (aged 31 and 48 years) who received partial hepatectomy due to trauma. The surgery time was from August 2006 to November 2009, and the follow-up deadline was September 2013 with a period of 4-7 years. The enrolled samples included 81 males and 9 females, aged 25-73 years with a median age of 54 years. Other clinical pathological indicators and survival conditions are shown in Table 3. The clinical staging was analyzed according to the HCC international TNM staging criteria published by American Joint Committee on Cancer (2012).
Table 3

Clinical pathological indicators and survival conditions of 90 HCC cases

ItemN (%)ItemN (%)
GenderTumor volume (cm3)
 Male81 (90.00)<12543 (47.78)
 Female9 (10.00)125≦V<100035 (38.89)
 Loss0≧100011 (12.22)
Age (year)Loss1 (1.11)
 <6066 (73.33)Pathological staging
 ≧6023 (25.56)I3 (3.33)
 Loss1 (1.11)II54 (60.00)
cTNM stagingIII33 (36.67)
 I11 (12.22)Loss0
 II29 (32.22)Survival condition
 III39 (43.33)Survival33 (36.67)
 IV3 (3.33)Death57 (63.33)
 Loss8 (8.89)Loss0

Preparation for tissue chips

Carcinoma tissues and normal control tissues were fixed in 10% formaldehyde solution, hydrated routinely, and embedded in paraffin blocks. The embedded tissues were sliced and stained with hematoxylin and eosin, which was further diagnosed by pathologists. The target tissues were marked under a microscope. A tissue microarray (Beecher Instruments Inc.) was used to punch in the receptor blank paraffin blocks (diameter 1.5 mm). The target tissue chip was obtained from the marked location and placed into the microarray. The aforementioned steps were repeated, and finally a 92-site microarray was achieved with carcinoma and normal control tissues. The 5-μm-thick slice thus obtained was adhered onto a glass slide, making a tissue chip.

Reagents

Goat anti-human Piwil2 polyclonal antibody (Piwil2(K-18):sc-67502) and rabbit anti-human Piwil4 polyclonal antibody (Piwil4(H-90):sc-68932) were obtained from Santa Cruz Biotechnology (Santa Cruz, USA). Cy3-labeled (red fluorescence) donkey anti-goat IgG (H+L) (A0502) was purchased from Beyotime Biotechnology (Jiangsu, China). IFKine Green-labeled (green fluorescence) donkey anti-rabbit IgG (H+L) (A24221) was obtained from Abbkine (California, USA). 4',6-Diamidino-2-phenylindole (DAPI) (D9542) was obtained from Sigma-Aldrich (Darmstadt, Germany). Anti-fluorescence quenching sealing liquid was purchased from Beyotime Biotechnology (Jiangsu, China).

Immunofluorescence double staining

The HCC tissue chips were dried in a 60°C oven and dewaxed. After repair under high pressure by antigen, the serum was added to the block. Then, the primary antibody (Piwil2 1:100; Piwil4 1:50) was added for incubation at 4°C overnight, and the fluorescent secondary antibody was added at 37°C and incubated avoiding light for 30 min. DAPI was used to stain for 10 min, and the chips were blocked by the anti-fluorescence quenching sealing liquid. The protein precipitation was observed under a fluorescence microscope. The tissue chips were read by two pathologists. Piwil2 protein showed red fluorescence (labeled by Cy3), and Piwil4 protein showed green fluorescence (labeled by TFKine Green). The cell nucleus showed blue fluorescence (stained by DAPI). The expression of Piwil2 or Piwil4 marker in HCC tissues was observed.

Statistical analysis

SPSS17.0 (SPSS, IL, USA) was used to analyze the data. Kaplan-Meier survival curve and log-rank test were used to analyze the correlation between the difference in the localization and expression of a single marker (Piwil2 or Piwil4) and molecular chaperone (Piwil2/Piwil4), and the prognosis of HCC. A P value <0.05 was considered statistically significant.
  27 in total

Review 1.  RNA-triggered gene silencing.

Authors:  A Fire
Journal:  Trends Genet       Date:  1999-09       Impact factor: 11.639

Review 2.  The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis.

Authors:  Michelle A Carmell; Zhenyu Xuan; Michael Q Zhang; Gregory J Hannon
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

Review 3.  RNAi and double-strand RNA.

Authors:  P A Sharp
Journal:  Genes Dev       Date:  1999-01-15       Impact factor: 11.361

4.  Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis.

Authors:  Chao Chen; Jianhua Liu; Guoxiong Xu
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

5.  DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes.

Authors:  Satomi Kuramochi-Miyagawa; Toshiaki Watanabe; Kengo Gotoh; Yasushi Totoki; Atsushi Toyoda; Masahito Ikawa; Noriko Asada; Kanako Kojima; Yuka Yamaguchi; Takashi W Ijiri; Kenichiro Hata; En Li; Yoichi Matsuda; Tohru Kimura; Masaru Okabe; Yoshiyuki Sakaki; Hiroyuki Sasaki; Toru Nakano
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

6.  Mili, a mammalian member of piwi family gene, is essential for spermatogenesis.

Authors:  Satomi Kuramochi-Miyagawa; Tohru Kimura; Takashi W Ijiri; Taku Isobe; Noriko Asada; Yukiko Fujita; Masahito Ikawa; Naomi Iwai; Masaru Okabe; Wei Deng; Haifan Lin; Yoichi Matsuda; Toru Nakano
Journal:  Development       Date:  2004-01-21       Impact factor: 6.868

Review 7.  PIWI proteins and PIWI-interacting RNAs in the soma.

Authors:  Robert J Ross; Molly M Weiner; Haifan Lin
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

Review 8.  Very small embryonic/epiblast-like stem cells: a missing link to support the germ line hypothesis of cancer development?

Authors:  Mariusz Z Ratajczak; Dong-Myung Shin; Magda Kucia
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

Review 9.  Cancer stem cells: the lessons from pre-cancerous stem cells.

Authors:  Jian-Xin Gao
Journal:  J Cell Mol Med       Date:  2007-12-05       Impact factor: 5.310

10.  Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients.

Authors:  Wei-Yu Kao; Yee Chao; Chun-Chao Chang; Chung-Pin Li; Chien-Wei Su; Teh-Ia Huo; Yi-Hsiang Huang; Yu-Jia Chang; Han-Chieh Lin; Jaw-Ching Wu
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  6 in total

1.  Novel piRNA MW557525 regulates the growth of Piwil2-iCSCs and maintains their stem cell pluripotency.

Authors:  Liming Jin; Zhaoxia Zhang; Zhang Wang; Xiaojun Tan; Zhaoying Wang; Lianju Shen; Chunlan Long; Guanghui Wei; Dawei He
Journal:  Mol Biol Rep       Date:  2022-04-11       Impact factor: 2.742

Review 2.  The emerging role of the piRNA/piwi complex in cancer.

Authors:  Yongmei Liu; Mei Dou; Xuxia Song; Yanhan Dong; Si Liu; Haoran Liu; Jiaping Tao; Wenjing Li; Xunhua Yin; Wenhua Xu
Journal:  Mol Cancer       Date:  2019-08-09       Impact factor: 27.401

3.  The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer.

Authors:  Weiyao Li; Javier Martinez-Useros; Nuria Garcia-Carbonero; Maria J Fernandez-Aceñero; Alberto Orta; Luis Ortega-Medina; Sandra Garcia-Botella; Elia Perez-Aguirre; Luis Diez-Valladares; Angel Celdran; Jesús García-Foncillas
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

4.  Emerging roles of piRNAs in cancer: challenges and prospects.

Authors:  Ye Cheng; Qian Wang; Wei Jiang; Yonghua Bian; Yang Zhou; Anxing Gou; Wenling Zhang; Kai Fu; Weihong Shi
Journal:  Aging (Albany NY)       Date:  2019-11-13       Impact factor: 5.682

Review 5.  PIWI-Interacting RNAs (piRNAs): Promising Applications as Emerging Biomarkers for Digestive System Cancer.

Authors:  Aiting Cai; Yuhao Hu; Zhou Zhou; Qianyi Qi; Yixuan Wu; Peixin Dong; Lin Chen; Feng Wang
Journal:  Front Mol Biosci       Date:  2022-01-27

Review 6.  Piwi-Interacting RNAs: A New Class of Regulator in Human Breast Cancer.

Authors:  Lu Qian; Heying Xie; Libo Zhang; Qian Zhao; Jinhui Lü; Zuoren Yu
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.